Methylprednisolone effective in treating critically ill patients
Recently, we announced that Advaita’s advanced AI platform, iPathwayGuide, was able to predict an existing drug with clinical efficacy against COVID-19. While the manuscript undergoes peer review, a preprint is available from Nature Research. Read the full article now!
Independent validation shows clinical efficacy
An independent clinical study undertaken at HFHS and led by Dr. Mayur S. Ramesh, has shown in a cohort of over 200 patients that a short course of methylprednisolone was able to significantly reduce transfers to ICU, requirements for ventilation, as well as mortality. A protocol was implemented on March 20, 2020 using early, short-course, methylprednisolone 0.5 to 1 mg/kg/day divided in 2 intravenous doses for 3 days. Outcomes of pre- and post-corticosteroid groups were evaluated. The patient cohort included 213 eligible subjects, 81 (38%) and 132 (62%) in pre-and post-MP groups, respectively. The mortality was reduced by approximately 50% from 26.3% to 13.6%. The respiratory failure requiring mechanical ventilation was reduced from 36.6% to 21.7% and the escalation to intensive care units was reduced from 44.3% to 27.3%. Full details can be found in the peer-reviewed article recently accepted for publication in the journal Clinical Infectious Diseases.
In addition to the paper submitted for peer-review, we intend to make all data, as well as the results of the analysis available in iPathwayGuide. If you are interested to access these data and the analysis, subscribe to our newsletter which will be used to announce when these are made available, as well as provide the details on how to access the data. Your contact information will not be shared with anyone.
Please note that this drug will not prevent infection and will not kill the virus. This is expected to be used only in severe cases, in a hospital setting, and should be administered only if deemed necessary by an attending physician.
Find the original press release here.